Skip to main content
. 2015 Jan 12;6:6047. doi: 10.1038/ncomms7047

Figure 3. Induction of Il6 by β-adrenergic signalling in adipocytes.

Figure 3

(a) Relative induction of Il6 expression after pharmaceutical activation of β-adrenergic signalling (10 μM isoproterenol and CL316,243) or adenylyl cyclase (50 μM forskolin). (b) Relative induction of Il6 by 10 μM CL316,243 after overexpression of green fluorescent protein control, IKK-ε wild type (WT) or IKK-ε kinase dead mutant (KD). (c) Expression of Il6 in cells treated with 10 μM CL316,243 after 1 h pretreatment with 100 μM amlexanox or vehicle control. (d) Relative Il6 expression in 3T3-L1 fibroblasts after 2 h amlexanox treatment. (e) Relative Il6 expression and (f) IL-6 secretion in RAW264.7 cells after 2 h of amlexanox treatment. (g) Relative Il6 expression and (h) IL-6 secretion in RAW264.7 cells after 2 h of 0.5 μg ml−1 lipopolysaccharide (LPS) treatment, with 1 h pretreatment with 2 μM Compound VIII. (i) Relative Il6 expression and (j) IL-6 secretion in RAW264.7 cells after 2 h of 50 μM forskolin treatment. * indicates P value<0.05 (student’s t-test (a,b,d) or two-way ANOVA plus Tukey–Krammer post-hoc analysis; c,g,h) versus control. # indicates P value<0.05 (two-way ANOVA plus Tukey–Krammer post-hoc analysis) vehicle versus anmelxanox (c) or Compound VIII versus control (g,h). Error bars presented as s.e.m.